Kiniksa Pharmaceuticals International, plc KNSA Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's deferred tax assets?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported deferred tax assets of $193.63M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's deferred tax assets changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's deferred tax assets decreased by 7.0% year-over-year, from $208.16M to $193.63M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's deferred tax assets?
- Over 4 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's deferred tax assets has grown at a 1086.4% compound annual growth rate (CAGR), from $10K to $198.15M.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.